ABSTRACT
China issued its Reimbursable Drug List in response to a number of emerging social issues surrounding medicine and healthcare. At the present time, the number of drugs included in the reimbursable drug list is gradually increasing, and the list has had a clear and positive impact on lowering the cost of drugs for patients and controlling the cost of what are called ‘pharmaceutical fees.’ Research methodology included surveying foreign and domestic literature, combing through and organizing policies, and summing up the results. China’s medical insurance funds are the largest ‘payer’ in China’s market for pharmaceuticals. Negotiated access has been a major innovation in recent years in the way in which drugs are admitted entry to the reimbursable drug list.
